The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Healthcare provider experiences in managing antibody-drug conjugate dosing adjustments due to nausea and vomiting: SABCS and ESMO survey findings.
 
Lee Schwartzberg
Consulting or Advisory Role - Abbvie; AstraZeneca; BMSi; Coherus Biosciences; Daiichi Sankyo; Epic Sciences; Foundation Medicine; Genentech; GlaxoSmithKline; Helsinn Therapeutics; Lilly; Napo Pharmaceuticals; Novartis; Pfizer; Sandoz; Sanofi; Seagen; Spectrum Pharmaceuticals
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Merck; Pfizer; Seagen
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Merck
 
Luca Licata
Consulting or Advisory Role - Accord Healthcare; AstraZeneca; Daiichi Sankyo; Exact Sciences; Italfarmaco; Lilly; Seagan
Speakers' Bureau - Exact Sciences; Gilead Sciences; Helsinn Healthcare; Lilly
Travel, Accommodations, Expenses - Accord Healthcare; Gilead Sciences; Lilly; Roche
 
Giampaolo Bianchini
Honoraria - AstraZeneca/Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; Lilly; Menarini; MSD; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Agendia; AstraZeneca; AstraZeneca/Daiichi Sankyo; Daiichi Sankyo Europe GmbH; Eisai; Exact Sciences; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Gilead Sciences (Inst)
Travel, Accommodations, Expenses - AstraZeneca/Daiichi Sankyo; Gilead Sciences; Novartis; Pfizer; Roche
 
Yeon Hee Park
Honoraria - AstraZeneca; Daiichi-Sankyo; Eisai; Gilead Sciences; Helsinn Healthcare; Lilly; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boryung; Daiichi-Sankyo; Eisai; Gilead Sciences; Lilly; Menarini; MSD; Novartis; Pfizer; Roche
Research Funding - AstraZeneca; Gencurix (Inst); Inocras (Inst); NGeneBio (Inst); Pfizer; Roche (Inst)
Travel, Accommodations, Expenses - Gilad
 
Eric Roeland
Consulting or Advisory Role - Dexcel Pharmaceuticals; Napo Pharmaceuticals; Ryvu Therapeutics
Research Funding - Pfizer (Inst)
Expert Testimony - HERON
 
Massimo Massagrande
Employment - Elma Research
Leadership - Elma Research
 
Francesca Dato
No Relationships to Disclose
 
Hirotoshi Iihara
Honoraria - Astellas Pharma; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Nippon Kayaku; Ohara Pharmaceutical; Sawai Pharmaceutical Co; Taiho Pharmaceutical; Yacult Honsha Co. Ltd
Consulting or Advisory Role - Astellas Pharma; Eisai; Taiho Pharmaceutical
 
Florian Scotte
Honoraria - Amgen; BMS GmbH & Co. KG; Daichy Sankyo; Gilead Sciences; GlaxoSmithKline; Leo Phar; Pfizer; Pharmanovia; Thermofisher Scientific Biomarkers; Viatris
Research Funding - Gilead Sciences
Travel, Accommodations, Expenses - Pfizer
 
Karin Jordan
Honoraria - Abbott Laboratories; Astellas Pharma; AstraZeneca; Fresenius; Helsinn Healthcare; Med Update; Merck Serono; Onkowissen; Pfizer; Roche
Consulting or Advisory Role - Abbott Laboratories; AstraZeneca; Helsinn Healthcare; Karyopharm Therapeutics; Pfizer
Patents, Royalties, Other Intellectual Property - Elsevier; Kluwer (UpToDate)
 
Matti Aapro
Consulting or Advisory Role - Daiichi Sankyo; Fresenius Kabi (Inst); Helsinn Healthcare; Lilly (Inst); Novartis (Inst); Pfizer (Inst)
Speakers' Bureau - Amgen; AstraZeneca; Genomic Health; Helsinn Healthcare; Mundipharma; Novartis; Pfizer; Vifor Pharma
Research Funding - Helsinn Healthcare (Inst); Helsinn Therapeutics (Inst); Novartis (Inst)
(OPTIONAL) Uncompensated Relationships - International Society for Geriatric Oncology SIOG
 
Hope Rugo
Honoraria - Chugai Pharma; Mylan/Viatris
Consulting or Advisory Role - Bristol Meyer; Napo Pharmaceuticals; Sanofi
Research Funding - Ambryx (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Hoffmann-La Roche AG/Genentech, Inc (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Stemline Therapeutics (Inst)